WalletHub | Jotup

Credit Acceptance Corporation Announces Tender Offer For Any and All of Its $400,000,000 Aggregate Principal Amount of 5.125% Senior Notes Due 2024

Retrieved on:

화요일, 12월 5, 2023

Telephone, Credit Acceptance, Letter, Note, CUSIP, Risk, Wells Fargo, Debt-to-GDP ratio, WalletHub, Security (finance), Annual report

Holders who validly tender (and do not validly withdraw) their Notes at or before the Expiration Time will receive $1,000 for each $1,000 principal amount of Notes accepted for purchase.

Key Points:

Holders who validly tender (and do not validly withdraw) their Notes at or before the Expiration Time will receive $1,000 for each $1,000 principal amount of Notes accepted for purchase.
Notes validly tendered in the Offer may not be withdrawn following the Expiration Time except in certain limited circumstances described in the Offer to Purchase.
This announcement is not an offer to purchase or a solicitation of an offer to sell any securities.
The Offer is being made solely by means of the Offer to Purchase and the related Letter of Transmittal.

Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)

Retrieved on:

월요일, 12월 4, 2023

FOX, Retirement, WalletHub

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”).

Key Points:

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”).
If you purchased Eagle securities and would like to discuss our investigation, your rights, or your interests please click here .
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.
For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com .

Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)

Retrieved on:

목요일, 11월 30, 2023

FOX, Retirement, WalletHub, Security (finance)

NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”).

Key Points:

NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”).
If you purchased Eagle securities and would like to discuss our investigation, your rights, or your interests please click here .
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.
For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com .

Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)

Retrieved on:

수요일, 11월 29, 2023

FOX, Retirement, WalletHub, Security (finance)

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”).

Key Points:

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”).
If you purchased Eagle securities and would like to discuss our investigation, your rights, or your interests please click here .
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.
For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com .

10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-Q Filing

Retrieved on:

화요일, 11월 28, 2023

Form, Notice, Bank statement, WalletHub, Letter, Security (finance), Medical device

New York, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by letter dated November 21, 2023 (the “Notice”), notified 10X III that it was not in compliance with the NYSE American LLC’s (“NYSE American”) continued listing standards because 10X III did not timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Quarterly Report”), which was due on November 20, 2023.

Key Points:

New York, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by letter dated November 21, 2023 (the “Notice”), notified 10X III that it was not in compliance with the NYSE American LLC’s (“NYSE American”) continued listing standards because 10X III did not timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Quarterly Report”), which was due on November 20, 2023.
As reported in the Form 12b-25 filed by 10X III with the Securities and Exchange Commission (“SEC”) on November 14, 2023, 10X III’s independent registered public accounting firm was still in the process of completing the review of the financial statements for the quarter ended September 30, 2023 and required additional time to complete its review of such financial statements.
The Notice provided that 10X III had a period of six months from the original due date of the Quarterly Report to file such report and that 10X III could regain compliance with the NYSE American’s continued listing standards at any time before that date by filing the Quarterly Report with the SEC and any other subsequent reports that are required to be filed during the cure period.
10X III subsequently cured its non-compliance with the continued listing standards of the NYSE American by filing the Quarterly Report on November 27, 2023.

CROWN PROPTECH ACQUISITIONS ANNOUNCES RECEIPT OF NOTICE OF LATE FILING FROM NYSE

Retrieved on:

화요일, 11월 28, 2023

Failure, Cayman Islands, Form, Form 10-Q, Bank statement, WalletHub, Security (finance)

The NYSE informed the Company that, under NYSE rules, the Company will have six months from November 20, 2023 to file the Form 10-Q with the SEC.

Key Points:

The NYSE informed the Company that, under NYSE rules, the Company will have six months from November 20, 2023 to file the Form 10-Q with the SEC.
The Company can regain compliance with the NYSE listing standards at any time prior to that date by filing its Form 10-Q.
The notice from the NYSE also notes that the NYSE may nevertheless commence delisting proceedings at any time if it deems that the circumstances warrant.
On November 14, 2023, the Company filed a Notification of Late Filing on Form 12b-25 (the “Form 12b-25”), indicating that the filing of its Form 10-Q will be delayed.

U.S. Global Investors Shares Optimism for Airline and Gold Sectors into Year-End, Receives Expected Nasdaq Notice Regarding Late Filing of Form 10-Q

Retrieved on:

수요일, 11월 22, 2023

Annual report, AAA, American Automobile Association, Tax, Travel, Mining, Form, Gold, ETF, News, Calendar, WalletHub, Form 10-Q, Cryptocurrency

“In fact, 4.7 million people are expected to fly over the Thanksgiving holiday this week.

Key Points:

“In fact, 4.7 million people are expected to fly over the Thanksgiving holiday this week.
Economic uncertainties and geopolitical tensions, for example, have heightened investor anxiety, prompting a shift toward historically safe-haven assets like gold.
“Investors are seeking stability in an increasingly volatile global economic landscape, a landscape we don’t see changing drastically anytime soon.
The Nasdaq notice has no immediate impact on the listing or trading of the Company’s common stock on the Nasdaq Capital Market.

Movella Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing

Retrieved on:

목요일, 11월 16, 2023

MVLA, Audit committee, Security (finance), Notice, Bank statement, Calendar, Movement, Software, Magazine, WalletHub, Medical device

The review and restatements are more fully described in Movella’s Current Report on Form 8-K filed on November 14, 2023.

Key Points:

The review and restatements are more fully described in Movella’s Current Report on Form 8-K filed on November 14, 2023.
Under Nasdaq rules, Movella now has 60 calendar days (until January 16, 2024) to submit a plan to regain compliance.
Movella continues to work expeditiously to conclude the review and file the Quarterly Report as soon as practicable.
There can be no assurance, however, that Movella will be able to regain compliance with the listing standards discussed above.

Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results

Retrieved on:

수요일, 11월 15, 2023

AGOURA HILLS, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today announced financial results for the three months ended September 30, 2023 (“Q3 2023”) as compared to the three months ended September 30, 2022 (“Q3 2022”).

Key Points:

AGOURA HILLS, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today announced financial results for the three months ended September 30, 2023 (“Q3 2023”) as compared to the three months ended September 30, 2022 (“Q3 2022”).
The financial results are based on the Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 14, 2023.
Highlights for Q3 2023 and thereafter:
We have been enjoying the effects of the benefits of the JV transaction, between Dragon Overseas Limited (“Dragon”) and us, through the formation of GMP Biotechnology Limited (“GMP Bio” or “JV”) being reflected in our financial results.
“Commencing April 2022, with the culmination of the JV with Dragon, and continuing into 2023 till date, have been a good eighteen months for us.

SharpLink Gaming Announces Third Quarter 2023 Financial Results

Retrieved on:

화요일, 11월 14, 2023

Webcast, SBET, Comparable, IGaming Business, Sport, WalletHub, Cryptocurrency

MINNEAPOLIS, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SharpLink Gaming Ltd. (Nasdaq: SBET) ("SharpLink" or the "Company"), a pioneer of targeted, data-driven fan activation and conversion solutions for the U.S. sports betting and iGaming industries, today announced its financial results for the three and nine months ended September 30, 2023.

Key Points:

Total revenues rose 153% to $3.27 million for the three months ended September 30, 2023 from $1.29 million for the same period in 2022.
For the comparable nine-month reporting periods, total revenues increased 101% to $9.92 million from $4.94 million.
All SharpLink business units achieved revenue growth in both the three and nine months ended September 30, 2023.
Commenting on the results, Rob Phythian, Chief Executive Officer of SharpLink, stated, “I believe we continued to execute well in the third quarter, delivering material growth in revenue and gross margin.